Citadel Advisors’s Avanos Medical AVNS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-10,700
| Closed | -$131K | – | 12731 |
|
|
2025
Q2 | $131K | Sell |
10,700
-2,500
| -19% | -$31.4K | ﹤0.01% | 11085 |
|
|
2025
Q1 | $189K | Buy |
13,200
+8,000
| +154% | +$125K | ﹤0.01% | 10530 |
|
|
2024
Q4 | $82.8K | Buy |
5,200
+200
| +4% | +$3.96K | ﹤0.01% | 11747 |
|
|
2024
Q3 | $120K | Sell |
5,000
-4,200
| -46% | -$96K | ﹤0.01% | 10879 |
|
|
2024
Q2 | $183K | Hold |
9,200
| – | – | ﹤0.01% | 10066 |
|
|
2024
Q1 | $183K | Buy |
9,200
+4,200
| +84% | +$81.2K | ﹤0.01% | 10453 |
|
|
2023
Q4 | $112K | Buy |
5,000
+2,500
| +100% | +$51.6K | ﹤0.01% | 10784 |
|
|
2023
Q3 | $50.5K | Buy |
2,500
+2,300
| +1,150% | +$52.1K | ﹤0.01% | 11745 |
|
|
2023
Q2 | $5.11K | Sell |
200
-1,200
| -86% | -$31.6K | ﹤0.01% | 13533 |
|
|
2023
Q1 | $41.6K | Buy |
1,400
+100
| +8% | +$2.9K | ﹤0.01% | 12389 |
|
|
2022
Q4 | $35.2K | Buy |
+1,300
| New | +$31.8K | ﹤0.01% | 12560 |
|
|
2020
Q4 | – | Sell |
-13,700
| Closed | -$455K | – | 10891 |
|
|
2020
Q3 | $455K | Sell |
13,700
-2,900
| -17% | -$92.7K | ﹤0.01% | 7466 |
|
|
2020
Q2 | $488K | Sell |
16,600
-14,600
| -47% | -$423K | ﹤0.01% | 7117 |
|
|
2020
Q1 | $840K | Buy |
31,200
+24,600
| +373% | +$735K | ﹤0.01% | 5634 |
|
|
2019
Q4 | $222K | Buy |
+6,600
| New | +$239K | ﹤0.01% | 8033 |
|
|
2019
Q2 | – | Sell |
-11,600
| Closed | -$495K | – | 9149 |
|
|
2019
Q1 | $495K | Buy |
11,600
+5,300
| +84% | +$237K | ﹤0.01% | 6796 |
|
|
2018
Q4 | $282K | Sell |
6,300
-11,100
| -64% | -$582K | ﹤0.01% | 7373 |
|
|
2018
Q3 | $1.19M | Sell |
17,400
-7,200
| -29% | -$463K | ﹤0.01% | 5241 |
|
|
2018
Q2 | $1.41M | Buy |
24,600
+4,700
| +24% | +$248K | ﹤0.01% | 4649 |
|
|
2018
Q1 | $917K | Buy |
19,900
+15,500
| +352% | +$736K | ﹤0.01% | 4955 |
|
|
2017
Q4 | $203K | Buy |
+4,400
| New | +$202K | ﹤0.01% | 7094 |
|
|
2016
Q3 | – | Sell |
-12,400
| Closed | -$403K | – | 7217 |
|
|
2016
Q2 | $403K | Buy |
12,400
+3,700
| +43% | +$113K | ﹤0.01% | 4780 |
|
|
2016
Q1 | $250K | Sell |
8,700
-2,400
| -22% | -$63.9K | ﹤0.01% | 5332 |
|
|
2015
Q4 | $371K | Sell |
11,100
-3,200
| -22% | -$99.5K | ﹤0.01% | 4893 |
|
|
2015
Q3 | $407K | Sell |
14,300
-11,100
| -44% | -$387K | ﹤0.01% | 5087 |
|
|
2015
Q2 | $1.03M | Sell |
25,400
-8,800
| -26% | -$395K | ﹤0.01% | 3926 |
|
|
2015
Q1 | $1.68M | Buy |
34,200
+25,900
| +312% | +$1.2M | ﹤0.01% | 3296 |
|
|
2014
Q4 | $377K | Buy |
+8,300
| New | +$326K | ﹤0.01% | 5108 |
|
Other funds holding AVNS
AC
VCM
VPM
Citadel Advisors's AVNS Position: Q1 2026 in Review
Citadel Advisors reduced its Avanos Medical (AVNS) stake by 0.72% in Q1 2026, selling an estimated $46.1K and leaving 475,196 shares worth $6.66M. The position accounts for ﹤0.01% of the portfolio, ranked #3875.
Citadel Advisors first reported a position in AVNS in Q4 2014 and has held it in 40 quarters since. The position peaked at $31.4M in Q2 2017. 257 funds tracked by Wall St. Rank hold AVNS as of Q1 2026.
- Citadel Advisors held 475,196 shares of Avanos Medical worth $6.66M as of Q1 2026.
- Citadel Advisors sold 3,424 Avanos Medical shares in Q1 2026, an estimated $46.1K.
- Avanos Medical made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3875 holding.
- Citadel Advisors first reported a position in Avanos Medical in Q4 2014 and has held it in 40 quarters since.
- Citadel Advisors's Avanos Medical position peaked at $31.4M in Q2 2017.
- 257 funds tracked by Wall St. Rank held Avanos Medical as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.